ADMA Biologics Enters Into $72.5 Million Loan Facility with Perceptive Advisors Provides Funding to Support Ongoing Activities Including Inventory Ramp, Plant Expansion, Product Launch and Plasma Collection Center Develo

ADMA Biologics Enters Into $72.5 Million

Loan Facility with Perceptive Advisors

Provides Funding to Support Ongoing

Activities Including Inventory Ramp, Plant Expansion, Product Launch and Plasma Collection Center Development

RAMSEY, N.J. and BOCA RATON, FL., - February 12, 2019

- ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial

biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics

for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that it has entered into

a senior secured term loan facility with Perceptive Advisors ("Perceptive") for up to $72.5 million under two funding

tranches. The first loan facility tranche from Perceptive of $45 million was used to prepay ADMA's former senior secured

credit facility of $30 million in full plus associated costs and fees. The second loan facility tranche from Perceptive of $27.5

million is predicated on United States Food and Drug Administration ("FDA") approval of either the BIVIGAM Prior

Approval Supplement or the RI-002 Biologics License Application and is available at ADMA's election through June 30, 2020,

with a minimum draw down of $10 million. The Perceptive loan facility provides for an interest only period through the entire duration

of the loan facility maturing in March 2022, as well as a more favorable interest rate as compared to ADMA's former senior

secured credit facility. Additionally, the new Perceptive loan facility does not include any back-end fees.

"This funding from Perceptive comes at an opportune time

for ADMA as we continue to move forward seeking approval for our immunoglobulin products BIVIGAM and RI-002," stated

Adam Grossman, President and Chief Executive Officer of ADMA. "As an existing equity holder in ADMA, Perceptive has an appreciable

understanding of our business, and we believe that providing this loan facility demonstrates their confidence in our business and

future prospects. This access to capital, combined with the potential FDA approvals of our product candidates, will allow us to

increase our manufacturing activities, initiate building additional plasma collection centers, and prepare for the potential commercialization

of BIVIGAM and RI-002 this year."

"Perceptive shares ADMA's vision of developing specialty

immunoglobulin therapeutics, and is pleased to provide additional capital to support the Company's product launch plans and

growth strategy," stated Sam Chawla, Portfolio Manager at Perceptive. "The Company has made significant progress since

acquiring the Boca Raton, FL manufacturing facility in 2017, including the improvement of the facility's compliance status

and obtaining new intellectual property for its proprietary product candidates. We look forward to ADMA's progress, and our

ability to fund the Company to drive important business objectives."

The Perceptive credit agreement has an interest only term with

a maturity date of March 1, 2022. Borrowings under the Perceptive credit agreement bear interest at a rate per annum equal to 7.5%

plus the greater of one-month LIBOR and 3.5%. ADMA will also issue a warrant to Perceptive priced at a 115% premium to purchase

1,360,000 shares of the Company's common stock.

The debt financing disclosed in this press release is not all

inclusive and, as such, the statements in this press release are qualified in their entirety by reference to the description of

the debt financing transaction and corresponding exhibits which are included in a Current Report on Form 8-K filed concurrently

with this press release by ADMA with the Securities and Exchange Commission.

ADMA Biologics, Inc. (ADMA)

ADMA Biologics is a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty

plasma-based biologics for the treatment of Primary Immune Deficiency Disease ("PIDD") and the prevention and treatment

of certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted

to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include

immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for other

medical reasons. ADMA has received U.S. Patents 9,107,906, 9,714,283, 9,815,886 and 9,969,793 related to certain aspects of its

lead product candidate, RI-002. For more information, please visit www.admabiologics.com.

About Perceptive Advisors

Founded in 1999 and based in New York, NY, Perceptive Advisors

is an investment management firm with over $3 billion in assets whose activities are focused on supporting the progress of the

life sciences industry by identifying opportunities and directing financial resources to the most promising technologies in healthcare.

For more information about Perceptive, visit www.perceptivelife.com.

BIVIGAM is an intravenous immune globulin indicated for

the treatment of primary humoral immunodeficiency. This includes, but is not limited to, agammaglobulinemia, common variable immunodeficiency,

Wiskott-Aldrich syndrome and severe combined immunodeficiency. These primary immunodeficiencies ("PI") are a group

of genetic disorders. Initially thought to be very rare, it is now believed that as many as 250,000 people in the U.S. have some

form of PI. BIVIGAM contains a broad range of antibodies similar to those found in normal human plasma. These antibodies are

directed against bacteria and viruses, and help to protect PIDD patients against serious infections. BIVIGAM is a purified,

sterile, ready-to-use preparation of concentrated polyclonal Immunoglobulin ("IgG") antibodies. Antibodies are proteins

in the human immune system that work to defend against infections and disease. FDA's initial approval for BIVIGAM was

received by Biotest Pharmaceuticals Corporation ("BPC" or "Biotest") on December 19, 2012, and production

of BIVIGAM was halted by Biotest in December 2016. ADMA Biologics obtained ownership and all rights, title and interest in

BIVIGAM on June 6, 2017 as part of the Biotest Therapy Business Unit ("BTBU") asset acquisition and resumed the

production of BIVIGAM during the fourth quarter of 2017.

ADMA's lead portfolio product candidate, RI-002, which has demonstrated

positive Phase III pivotal clinical trial data, is a specialty plasma-derived, polyclonal, intravenous immune globulin ("IVIG")

derived from human plasma containing naturally occurring polyclonal antibodies (e.g., Streptococcus pneumoniae, H. influenza type

B, cytomegalovirus ("CMV"), measles, tetanus, etc.) as well as plasma from donors tested to have high levels of neutralizing

antibodies to respiratory syncytial virus ("RSV"). ADMA is pursuing an indication for the use of this specialty polyclonal

IVIG product for treatment of patients diagnosed with PIDD. Polyclonal antibodies are the primary active component of IVIG products.

Polyclonal antibodies are proteins that are used by the body's immune system to neutralize microbes, such as bacteria and viruses

and prevent against infection and disease. Data review which has been published in peer reviewed journals indicates that the polyclonal

antibodies present in RI-002 support its ability to prevent infections in immune-compromised patients. This data and other information

about RI-002 or ADMA Biologics products can be found on the Company website at: www.admabiologics.com. RI-002 is protected by U.S.

Patents: 9,107,906, 9,714,283, 9,815,886 and 9,969,793, the latter of which affords the Company patent exclusivity for the use

of an immune globulin as a prevention and/or treatment for any type of respiratory infection.

About Primary Immune Deficiency Disease (PIDD)

PIDD is a class of inherited genetic disorders that causes an

individual to have a deficient or absent immune system. According to the World Health Organization, there are approximately 350

different genetic mutations encompassing PIDD. Some disorders present at birth or in early childhood, the disorders can affect

anyone regardless of age or gender. Some affect a single part of the immune system, others may affect one or more components of

the system. PIDD patients are vulnerable to infections and more likely to suffer complications from these infections as compared

to individuals with a normal functioning immune system. The infections may occur in any part of the body. As patients suffering

from PIDD lack a properly functioning immune system, they typically receive monthly treatment with polyclonal immune globulin products.

Without this exogenous antibody replacement, these patients would remain vulnerable to persistent and chronic infections. PIDD

has an estimated prevalence of 1:1,200 in the United States, or approximately 250,000 people in the U.S.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements"

pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. ("we",

"our" or the "Company"). Forward-looking statements include, without limitation, any statement that may

predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate,"

"project," "intend," "forecast," "target," "anticipate," "plan,"

"planning," "expect," "believe," "will," "is likely," "will likely,"

"should," "could," "would," "may," or, in each case, their negative, or words or expressions

of similar meaning. These forward-looking statements also include, but are not limited to, statements concerning our plans to develop,

manufacture, market, launch and expand our own commercial infrastructure and commercialize our current products and future products,

the safety, efficacy and expected timing of, and our ability to, obtain and maintain regulatory approvals of our current products

and product candidates, and the labeling or nature of any such approvals, the success of our work with our third party vendors

and the U.S. Food and Drug Administration (the "FDA") in furtherance of and progress towards an approval of our Biologics

License Application for specialty plasma-based biologics and the ability of such third parties to respond adequately or in a timely

manner to the issues raised by the FDA, our ability to successfully pursue commercialization and prelaunch activities, the timeframe

within which we may receive approval from the FDA for specialty plasma-based biologics, if at all, the potential of our specialty